secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lipocine Inc. (LPCN)
CIK:        0001535955
Form:       8-K
Filed at:   2024-10-23T23:59:59+00:00
Accession:  0001493152-24-042117
Event type: other_material
Sentiment:  neutral
Materiality: 0.25
Item codes: 1.01, 3.03, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lipocine extends stockholder rights plan to October 2027; amends preferred stock certificate
--------------------------------------------------------------------------------

- Third Amended and Restated Rights Agreement extends expiration to October 22, 2027 (from November 1, 2024).
- No material changes to the plan; Rights remain exercisable at $30.24 per one-thousandth of Series A Preferred.
- Certificate of Amendment filed to reflect impact of May 2023 reverse stock split on preferred stock designation.
- Rights become exercisable if a person acquires 15%+ of common stock; designed to deter coercive takeovers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1535955/000149315224042117/0001493152-24-042117-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1535955/000149315224042117/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-042117

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer